The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

Compositions that provide sustained energy up to 8 hours with an amount of caffeine that is less than 25 mg are described. The compositions comprise at least an astragaloside compound, a ginsenoside compound, a stilbenoid compound, and caffeine. Many of the compositions further comprise an amino acid having anabolic properties (e.g., having a role in the regulation of protein metabolism), including one or more of the group of arginine, ornithine, citrulline, glutamine, and a precursor, analog, prodrug, and/or derivative thereof, as well as molecules that interact with arginosuccinate synthase and/or arginosuccinate lyase, and analogs, prodrugs and derivatives thereof. Methods of utilizing the described compositions include administering orally to a subject an effective amount of the described composition, such that the composition provides sustained energy for up to 8 hours with an amount of caffeine in the composition administered orally that is less than 25 mg.

Compositions that provide sustained energy up to 8 hours with an amount of caffeine that is less than 25 mg are described. The compositions comprise at least an astragaloside compound, a ginsenoside compound, a stilbenoid compound, and caffeine. Many of the compositions further comprise an amino acid having anabolic properties (e.g., having a role in the regulation of protein metabolism), including one or more of the group of arginine, ornithine, citrulline, glutamine, and a precursor, analog, prodrug, and/or derivative thereof, as well as molecules that interact with arginosuccinate synthase and/or arginosuccinate lyase, and analogs, prodrugs and derivatives thereof. Methods of utilizing the described compositions include administering orally to a subject an effective amount of the described composition, such that the composition provides sustained energy for up to 8 hours with an amount of caffeine in the composition administered orally that is less than 25 mg.

The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a -3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a -3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a -3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a -3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

The present invention relates to methods for supplementing the diet of subjects suffering from cardiovascular disease. D-Ribose is given long term alone or in combination with vasodilators in order to improve or maintain the diastolic or systolic function of the subjects.

The present invention relates to methods for supplementing the diet of subjects suffering from cardiovascular disease. D-Ribose is given long term alone or in combination with vasodilators in order to improve or maintain the diastolic or systolic function of the subjects.